Shots:

• The EMA’s CHMP has adopted the positive opinion recommending the approval of two biosimilar bevacizumab medicines- Alymsys and Oyavas for the treatment of carcinoma of the colon or rectum- breast cancer- NSCLC- RCC- epithelial ovarian- fallopian tube or primary peritoneal cancer- and carcinoma of the cervix
• Mabxience’s Alymsys and STADA’s Oyavas both show comparable quality- safety & efficacy to Avastin (bevacizumab)
• Oyavas and Alymsys will be available as 25 mg/ml concentrate for solution for infusion

Source 1- Source 2 ­

 Ref: EMA | Image: Europa EU